Previous close | 1.400 |
Open | 1.430 |
Bid | 1.410 x 0 |
Ask | 1.420 x 0 |
Day's range | 1.370 - 1.430 |
52-week range | 1.210 - 2.870 |
Volume | |
Avg. volume | 890,099 |
Market cap | 1.438B |
Beta (5Y monthly) | 0.63 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.150 |
Earnings date | 25 Mar 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 3.05 |
Ascletis Pharma Inc. (HKEX:1672, "Ascletis") announces today the strategic decisions on farnesoid X receptor (FXR) agonist ASC42.
Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces the poster presentation of Phase II study final results of ASC40, a first-in-class fatty acid synthase (FASN) inhibitor for treatment of acne, at the 2024 American Academy of Dermatology (AAD) Annual Meeting in San Diego, the United States.
Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces dosing of the first patient in Phase III clinical trial of ASC40 (Denifanstat) for treatment of moderate to severe acne vulgaris at Huashan Hospital, Fudan University.